 Leigh Casadaban
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chemoembolization, Therapeutic | 5 | 2016 | 91 | 1.870 |
Why?
| | Liver Neoplasms | 7 | 2021 | 786 | 1.600 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 5 | 2015 | 44 | 1.540 |
Why?
| | Embolization, Therapeutic | 3 | 2022 | 229 | 1.330 |
Why?
| | Osteoarthritis, Knee | 2 | 2022 | 254 | 1.180 |
Why?
| | Colonic Neoplasms | 3 | 2017 | 258 | 0.980 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2016 | 362 | 0.830 |
Why?
| | End Stage Liver Disease | 2 | 2015 | 82 | 0.820 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2021 | 98 | 0.700 |
Why?
| | Pain Management | 2 | 2022 | 352 | 0.690 |
Why?
| | Arthralgia | 1 | 2020 | 56 | 0.660 |
Why?
| | Knee Joint | 1 | 2022 | 409 | 0.600 |
Why?
| | Leg | 1 | 2020 | 236 | 0.600 |
Why?
| | Ethiodized Oil | 2 | 2016 | 8 | 0.530 |
Why?
| | Hepatic Artery | 2 | 2015 | 62 | 0.530 |
Why?
| | Liver Transplantation | 2 | 2014 | 871 | 0.490 |
Why?
| | Esophageal and Gastric Varices | 1 | 2015 | 40 | 0.460 |
Why?
| | Hepatic Encephalopathy | 1 | 2014 | 21 | 0.450 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2014 | 3 | 0.450 |
Why?
| | Biliary Tract | 1 | 2014 | 17 | 0.450 |
Why?
| | Liver Function Tests | 1 | 2014 | 114 | 0.440 |
Why?
| | Leukemia | 1 | 2017 | 240 | 0.440 |
Why?
| | Hypertension, Portal | 1 | 2014 | 64 | 0.440 |
Why?
| | Jugular Veins | 1 | 2014 | 41 | 0.440 |
Why?
| | Emergencies | 1 | 2015 | 164 | 0.430 |
Why?
| | Doxorubicin | 1 | 2016 | 362 | 0.430 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2015 | 132 | 0.430 |
Why?
| | Adenocarcinoma | 2 | 2017 | 940 | 0.390 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 301 | 0.360 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1692 | 0.340 |
Why?
| | Thrombosis | 1 | 2013 | 371 | 0.310 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 135 | 0.300 |
Why?
| | Survival Rate | 5 | 2016 | 1972 | 0.300 |
Why?
| | Retrospective Studies | 11 | 2023 | 15657 | 0.260 |
Why?
| | Liver | 2 | 2018 | 1943 | 0.260 |
Why?
| | Colectomy | 2 | 2017 | 100 | 0.250 |
Why?
| | Middle Aged | 14 | 2021 | 33479 | 0.250 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 2129 | 0.250 |
Why?
| | Chicago | 2 | 2014 | 61 | 0.230 |
Why?
| | Angiography | 3 | 2014 | 207 | 0.230 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7635 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2021 | 10811 | 0.220 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1389 | 0.210 |
Why?
| | Hyperaldosteronism | 1 | 2023 | 8 | 0.210 |
Why?
| | Biomarkers | 1 | 2015 | 4149 | 0.210 |
Why?
| | Humans | 20 | 2023 | 137585 | 0.200 |
Why?
| | Aged | 9 | 2021 | 23961 | 0.200 |
Why?
| | Female | 16 | 2021 | 73304 | 0.190 |
Why?
| | Arteries | 1 | 2022 | 269 | 0.170 |
Why?
| | Male | 14 | 2018 | 67762 | 0.170 |
Why?
| | Rabbits | 3 | 2016 | 794 | 0.160 |
Why?
| | Nitrogen Radioisotopes | 1 | 2018 | 5 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 389 | 0.150 |
Why?
| | Pain Measurement | 1 | 2020 | 521 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5131 | 0.140 |
Why?
| | Ablation Techniques | 1 | 2018 | 36 | 0.140 |
Why?
| | Incidence | 2 | 2014 | 2804 | 0.140 |
Why?
| | Propensity Score | 2 | 2016 | 294 | 0.140 |
Why?
| | Pain | 1 | 2022 | 756 | 0.130 |
Why?
| | Radiography, Interventional | 1 | 2018 | 116 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 294 | 0.130 |
Why?
| | In Situ Nick-End Labeling | 1 | 2016 | 124 | 0.120 |
Why?
| | Illinois | 1 | 2015 | 43 | 0.120 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2015 | 31 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2016 | 307 | 0.120 |
Why?
| | Paracentesis | 1 | 2015 | 14 | 0.120 |
Why?
| | Prosthesis Fitting | 1 | 2015 | 15 | 0.120 |
Why?
| | Hepatic Veins | 1 | 2015 | 33 | 0.120 |
Why?
| | Ascites | 1 | 2015 | 46 | 0.110 |
Why?
| | Niacinamide | 1 | 2015 | 82 | 0.110 |
Why?
| | Dilatation | 1 | 2015 | 67 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 97 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2014 | 25 | 0.110 |
Why?
| | Adult | 7 | 2021 | 37929 | 0.110 |
Why?
| | Subtraction Technique | 1 | 2013 | 23 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2015 | 229 | 0.100 |
Why?
| | Pilot Projects | 2 | 2018 | 1710 | 0.100 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 245 | 0.100 |
Why?
| | Vena Cava, Inferior | 1 | 2013 | 71 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.100 |
Why?
| | Vena Cava Filters | 1 | 2013 | 61 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2016 | 365 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2691 | 0.100 |
Why?
| | Device Removal | 1 | 2013 | 136 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2017 | 556 | 0.100 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 316 | 0.100 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 153 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.090 |
Why?
| | Risk Factors | 3 | 2015 | 10388 | 0.090 |
Why?
| | Reoperation | 1 | 2014 | 573 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1062 | 0.090 |
Why?
| | Venous Thrombosis | 1 | 2013 | 190 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2015 | 956 | 0.090 |
Why?
| | Transcriptome | 1 | 2017 | 971 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1946 | 0.080 |
Why?
| | Endovascular Procedures | 1 | 2013 | 312 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2014 | 683 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1313 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4030 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3284 | 0.060 |
Why?
| | Disease Progression | 1 | 2014 | 2757 | 0.060 |
Why?
| | Radiopharmaceuticals | 2 | 2018 | 178 | 0.060 |
Why?
| | Cohort Studies | 1 | 2016 | 5742 | 0.060 |
Why?
| | Aldosterone | 1 | 2023 | 45 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2023 | 78 | 0.050 |
Why?
| | Animals | 3 | 2016 | 36940 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 722 | 0.040 |
Why?
| | Young Adult | 1 | 2014 | 13209 | 0.040 |
Why?
| | Microwaves | 1 | 2018 | 37 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2017 | 45 | 0.030 |
Why?
| | Fluorouracil | 1 | 2017 | 208 | 0.030 |
Why?
| | Injections, Intra-Arterial | 1 | 2015 | 27 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 132 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2015 | 124 | 0.030 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 2014 | 6 | 0.030 |
Why?
| | Gamma Cameras | 1 | 2014 | 8 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2015 | 4295 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 118 | 0.030 |
Why?
| | Yttrium Radioisotopes | 1 | 2014 | 57 | 0.030 |
Why?
| | Phlebography | 1 | 2013 | 38 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 257 | 0.030 |
Why?
| | Hindlimb | 1 | 2014 | 128 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1325 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2013 | 51 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2015 | 327 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 822 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 955 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1113 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2015 | 916 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1587 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3556 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2828 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3412 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7604 | 0.020 |
Why?
| | United States | 1 | 2017 | 14841 | 0.010 |
Why?
|
|
Casadaban's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|